Overview

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Status:
WITHDRAWN
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter. In addition to collecting safety data for the imaging agent, the study aims to: * compare the findings against other catacholamine transporters * evaluate the imaging results at different time points and in different organs * assess the quality of images with lower doses * compare the ability to detect neuroblastoma lesions against other imaging agents, and in other tumors
Phase:
PHASE2
Details
Lead Sponsor:
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Collaborator:
Albert Einstein College of Medicine
Treatments:
3-fluorobenzylguanidine